Citations

Clear

16280 citation(s) found for "Yu, David".

Revisiting Minimum Case Volume Recommendations for Complex Surgery in Contemporary Practice
Kartik, Akash , Stucky, Chee-Chee, Etzioni, David A. , Bold, Richard J. , Wasif, Nabil , Ven Fong, Zhi, Cronin, Patricia A. , Etzioni, David, Bold, Richard, Fong, Zhi Ven , Chang, Yu‐Hui

Mayo Clinic

JAMA | October 8, 2025 | Volume: 334 | Issue: 21 | Pages: 1945

10.1001/jama.2025.17274 | PMID 41060621 Get It

This study examines the relevance of minimum case volume recommendations in contemporary practice.
Interrater and Intrarater Reliability of Mohs Surgeons in the Assessment of MART-1 Frozen Section Margins for Melanoma
Freeman, S. Caleb , Shahwan, Kathryn T. , Aasi, Sumaira Z. , Brewer, Jerry D., Brodland, David G., Christensen, Sean R. , Demer, Addison M. , Holmes, Todd, Nijhawan, Rajiv I. , Saylor, Drew K. , Sobanko, Joseph F. , Zitelli, John A. , Lucero, Olivia M. , Bar, Anna, Carr, David R. , Leitenberger, Justin J. , Miller, Christopher J. , Bordeaux, Jeremy S. , Etzkorn, Jeremy R. , Kibbi, Nour , Maher, Ian A. , Srivastava, Divya , Latour, Emile J. , Yu, Wesley Y. , Carr, David R.

Mayo Clinic

Dermatologic Surgery | October 8, 2025 | Volume: 52 | Issue: 5 | Pages: 421-427

10.1097/dss.0000000000004906 | PMID 41060146 Get It

BACKGROUND The use of Mohs micrographic surgery as a treatment for melanoma is rising, but the reliability of Mohs surgeons in assessing MART-1 melanoma en-face margins has not been evaluated. OBJECTIVE To evaluate interrater and intrarater reliability of Mohs surgeons in interpreting margins of early-stage melanoma. METHODS Twenty Mohs surgeons were asked to independently review images of frozen section MART-1 en-face peripheral margins of in situ or early-stage melanoma. Surgeons determined margins as positive or negative at initial evaluation and 6 weeks later. Primary outcomes were interrater and intrarater reliability. RESULTS Interrater agreement was 84.1% (95% confidence interval [CI]: 75.5%–92.8%) for assessment 1 and 87.5% (95% CI: 78.4%–96.4%) for assessment 2, with kappa values 0.68 (95% CI: 0.50–0.82) and 0.75 (95% CI: 0.57–0.88). Average intrarater percent agreement was 95.0% (95% CI: 70.6%–100.0%) with average kappa 0.90 (95% CI: 0.50–1.00). CONCLUSION Substantial interrater and nearly perfect intrarater agreement was identified among surgeons assessing melanoma margins utilizing MART-1 immunostaining, demonstrating consistent and reproducible assessment of melanoma margins during Mohs cases.
From GWAS to Translational Insights: Comprehensive Genetic Analysis of Nephrotic Syndrome from Multiple Populations
Seagle, Hannah M. , Akerele, Alexis T., Ahn, Kwangmi , Torstenson, Eric S. , Zhang, Yanfei , Jarvik, Gail P., Dikiltas, Ozan, Lee, Ming Ta Michael , Fargo, David C. , Rowley, Robb , Kiryluk, Krzysztof, Hellwege, Jacklyn N. , Breeyear, Joseph H. , Khankari, Nikhil K. , Burkholder, Adam , House, John S. , Kullo, Iftikhar J. , Kiryluk, Krzysztof , Woychik, Richard P. , Motsinger‐Reif, Alison A. , Suszták, Katalin , Edwards, Todd L.

Mayo Clinic

No container title available | October 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7482306/v1 Get It

Abstract Nephrotic syndrome is a rare, heterogeneous kidney disorder characterized by proteinuria, hypoalbuminemia, and edema. To elucidate its genetic architecture, we conducted a large-scale, electronic health record (EHR)-linked, multi-ancestry genome-wide association study comprising 5,214 cases and 1,601,060 controls. We identified 37 distinct loci associated with disease risk, including novel associations at JAML and STPG2 , and confirmed prior signals at PLA2R1 , HMCN1 , and APOL1 . Fine-mapping of the major histocompatibility complex (MHC) revealed the strongest association at DRB103:01:01G in individuals of European ancestry (OR = 2.01, P = 1.4×10⁻²⁰), alongside nominal ancestry-specific associations in African ( DOA01:01:05 ) and Latino ( DPB1*14:01:01G ) populations. Transcriptome-wide association analysis (TWAS) identified 484 significant gene-tissue associations, including C4A in kidney cortex. Expression quantitative trait locus (eQTL) mapping revealed numerous cis-eQTLs in glomerular and tubular renal tissues, largely within the MHC region. We observed significant genetic correlation between adult and pediatric nephrotic syndrome (Rg = 0.63, P = 3.5x10 -11 ), suggesting shared genetic etiology. Pathway analyses implicated estrogen receptor signaling and histone modification. Mendelian randomization implicated APOM expression and apomorphine exposure with increased disease risk (OR = 4.93, P = 1.8x10 -19 ). These results expand the understanding of nephrotic syndrome pathogenesis and highlight ancestry-informed targets for therapeutic development.
Passive Leg Raise Does Not Unmask Diastolic Dysfunction in Adults With Fontan Circulation
Cao, Jacob , Jain, C. Charles , Egbe, Alexander C. , Borlaug, Barry A. , Reddy, Yogesh N.V. , Celermajer, David S. , Miranda, William R. , Cao, Jacob Y , Celermajer, David , Cordina, Rachael , Miranda, William R , Nishimura, Rick , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | October 8, 2025 | Volume: 18 | Issue: 12 | Pages: No page available

10.1161/circheartfailure.125.012991 | PMID 41058574 Get It

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
Cerhan, James R. , Соколова, Т. Н. , Cahn, Elliot, Tsang, Mazie , Strouse, Christopher , Hildebrandt, Michelle A.T. , Feldman, Andrew L. , Jaye, David L. , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Thompson, Carrie A. , Flowers, Christopher R. , Sokolova, Tereza, Cahn, Elliott J, Strouse, Christopher S , Rosenthal, Allison , Feldman, Andrew L , Jaye, David L , Martin, Peter , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Friedberg, Jonathan W , Nastoupil, Loretta J , Link, Brian K , Habermann, Thomas , Maurer, Matthew , Casulo, Carla , Thompson, Carrie A , Williams, Annalynn M , Flowers, Christopher R , Cerhan, James R , Hildebrandt, Michelle A T , Tsang, Mazie , Sokolova, Tereza, Kahl, Brad S. , Nastoupil, Loretta J. , Link, Brian K. , Habermann, Thomas M. , Maurer, Matthew J. , Casulo, Carla

Mayo Clinic

Hematological Oncology | October 8, 2025 | Volume: 43 | Issue: 6 | Pages: No page available

10.1002/hon.70137 | PMID 41057230 Get It

ABSTRACT Newly diagnosed patients with non‐Hodgkin lymphoma (NHL) often have a history of other diseases, and these comorbidities can impact patient treatment and management options, as well as overall survival (OS). We developed the Lymphoma Epidemiology of Outcomes (LEO) comorbidity index (LCI) as a sum of 10 comorbidities adapted from the Self‐Report‐Generated Charlson Comorbidity Index (SRG‐CCI) for use in the LEO cohort, a national prospective study of newly diagnosed NHL. Of the 5502 participants with self‐reported comorbidity data, 3107 (56.4%) were male and the mean age at diagnosis was 60.9 years (range, 18–99 years). The LCI ranged from 0 to 6, with 48.6% having 0, 30.2% having 1, 21.2% having 2 or more comorbidities. With a median follow‐up of 62.4 months among surviving participants, 2099 patients had an event and 1219 died. Continuous LCI similarly predicted both 1‐year mortality (c‐statistic = 0.654) and OS (c‐statistic = 0.655), while it showed a weaker but still statistically significant predictive ability for lymphoma‐specific (c‐statistics = 0.617) and event‐free (c‐statistic = 0.574) survival. Participants with 1 (HR = 1.21, 95% CI 1.05–1.39) and 2+ (HR = 1.80, 95% CI 1.56–2.08) comorbidities had inferior OS compared to those with no comorbidities after adjustment for age and sex (c‐statistic = 0.654), and performance strengthened after adjustment for the International Prognostic Index (c‐statistic = 0.672). LCI predicted OS most strongly in marginal zone (c‐statistics = 0.748) and weakest in T‐cell (c‐statistic = 0.579) lymphoma. The cumulative incidence of death due to lymphoma, lymphoma treatment, and other causes all increased with increasing comorbidities, with the greatest increase observed for death due to other causes. The LCI performs comparable to other published comorbidity indices, supporting its use in the LEO cohort to better model real‐world outcomes and more generally providing an approach to implementing comorbidity indices in cancer survivorship cohorts.
Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma
Charalampous, Charalampos , Parrondo, Ricardo , Nagaraj, Madhu , Rodríguez‐Otero, Paula , Iida, Shinsuke , Raab, Marc S. , Mateos, María‐Victoria , Duh, Mei Sheng , Bobbili, Priyanka , Chen, Jingyi , Chaudhary, Mohammad A. , Hlavacek, Patrick , Nador, Guido, DiBonaventura, Marco , Goldman, Erinn Hoag, Hughes, David , Kumar, Shaji , Raab, Marc S , Parrondo, Ricardo D , Rodriguez-Otero, Paula , Chhabra, Saurabh , Nagaraj, Madhu , Wang, Aolin , Mohty, Mohamad

Mayo Clinic

JCO Oncology Advances | October 7, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00009 Get It

PURPOSE This analysis aimed to contextualize the symptoms of peripheral neuropathy (PN) experienced by patients with triple-class refractory (TCR) multiple myeloma (MM) treated with elranatamab in the MagnetisMM-3 clinical trial with those experienced by patients with TCR MM receiving a new line of physician's choice of therapy in the real-world MagnetisMM-14 study. METHODS MagnetisMM-3 included 123 patients and MagnetisMM-14 included 35 who had TCR MM and were enrolled under the same eligibility criteria. Patient-reported symptoms of PN were collected monthly using the Chemotherapy-Induced Peripheral Neuropathy-20 item (CIPN20) questionnaire and compared for clinically meaningful differences across sensory, motor, and autonomic domains. Higher scores indicated worse patient-reported PN symptoms. RESULTS Baseline demographics and clinical characteristics for patients in MagnetisMM-3 and MagnetisMM-14 were generally similar. Patients in MagnetisMM-3 had a median of five ( v four in MagnetisMM-14) prior lines of therapy. In MagnetisMM-14, common index therapies included elotuzumab + pomalidomide (23%), carfilzomib + pomalidomide (19%), or carfilzomib + cyclophosphamide (19%), all with corticosteroids. Mean scores for sensory (15.8 v 14.8) and motor (14.4 v 12.2) domains of the CIPN20 were similar between MagnetisMM-3 and MagnetisMM-14 at baseline. Mean scores for the autonomic domain were 14.0 versus 21.3 at baseline, respectively. No clinically meaningful differences for any domain were found between month 6 scores or changes in scores from baseline to month 6 between MagnetisMM-3 and MagnetisMM-14 populations. CONCLUSION These findings suggest that elranatamab treatment was not associated with a worsening of patient-reported PN symptoms across the sensory, motor, and autonomic domains of the CIPN20. Moreover, PN symptoms reported with elranatamab treatment were similar to those reported with other common therapies used in real-world clinical practice for the management of MM. MagnetisMM-3 ClinicalTrials.gov identifier: NCT04649359 .
Improving documented rates of comprehensive vaccination status assessment and vaccination recommendation in patients receiving chemotherapy at a breast medical oncology clinic.
Greenmyer, Jacob R. , Hoppenworth, Jenna, Huschka, David J., Volety, Rama, Taraba, Jodi L. , Tevaarwerk, Amyé , Volety, Rama , Taraba, Jodi L , Allen‐Rhoades, Wendy

Mayo Clinic

JCO Oncology Practice | October 7, 2025 | Volume: 21 | Issue: 10_suppl | Pages: 431-431

10.1200/op.2025.21.10_suppl.431 Get It

431 Background: The National Adult and Influenza Immunization Summit (NAIIS) promoted clinical subspecialist efforts toward vaccination assessment and recommendation as one strategy to increase adult vaccination rates. Problem Statement: Between August 1, 2022, and May 31, 2023, 0% (n=0/100) of patients seen in medical oncology at Mayo Clinic (Rochester, MN) and receiving chemotherapy for breast cancer had a documented comprehensive vaccination status assessment by breast medical oncology staff. Aim Statements: (1) To increase the rate of comprehensive vaccination status assessment performed by breast medical oncology staff from 0% to 75% of patients receiving chemotherapy for breast cancer by September 2024. (2) To increase the rate of documented vaccination recommendation for patients who were not up to date with recommended vaccinations from 0% to 50% by September 2024. Methods: We deployed multiple interventions including physician and nurse education; development of patient education materials; and a standard operating procedure (SOP) for vaccination status assessment, vaccination recommendation, and vaccine-related documentation. Our SOP utilized an Epic SmartPhrase with following elements: (1) SmartLink that autopopulated overdue vaccinations, (2) hidden tip text permitting the use to hyperlink to Health Maintenance, (3) SmartLists that captured nurse actions (e.g., provided education) and encounter outcomes (e.g., patient endorsed plans to receive vaccinations), and (4) scripting for immunization education. Results: Multi-faceted interventions were associated with an improvement in the documented rate of comprehensive vaccination status assessment from 0% (n=0/100) to 82.8% (n=101/122). Most patients (77.2%, n=78/101) were not up to date with recommended vaccinations. Recommendations for appropriate vaccinations were made for 80.8% (n=63/78) of patients who were not up to date. Only 19.2% (n=15/78) of patients who were not up to date endorsed intention to receive missing/recommended vaccines. Counterbalance: Nurses were able to assess vaccination status and make appropriate recommendations in less than 5 minutes per patient. There was no difference in nurse-reported workflow burden related to vaccination status assessment, recommendation, or documentation after intervention. Conclusions: This quality project aligned our breast medical oncology practice with vaccination-related care promoted by NAIIS. We increased rates of vaccination status assessment and vaccination recommendations without impacting nurse-reported workflow burden. Medical subspecialty clinic engagement in vaccination efforts is feasible.
The growing burden of prior authorization: A national survey.
Gracie, Jayden , Sim, Austin J. , Gardner, Liz, Beatley, Emilio, Chen, Xuguang , Sharifzadeh, Yasamin , Winkfield, Karen M. , Chin, Alexander L. , Paravati, Anthony J., Luh, Join Y. , Barnes, Justin M. , Beatley, Emilio, Bates, James E. , Shen, Xinglei , Hong, David S. , Sio, Terence T. , Jimenez, Rachel , Chino, Fumiko

Mayo Clinic

JCO Oncology Practice | October 7, 2025 | Volume: 21 | Issue: 10_suppl | Pages: 98-98

10.1200/op.2025.21.10_suppl.98 Get It

98 Background: Prior authorization (PA) purports to control costs and ensure adherence to evidence-based guidelines but negatively impacts cancer care. Radiation oncology (RO) represents a minority of overall cancer spending yet bears a disproportionately high PA burden. Limited research exists on the effects of PA on patient outcomes and administrative workload within RO clinics. Methods: From 9/2024 to 10/2024, an online survey was open to U.S. members of the American Society for Radiation Oncology assessing experiences with PA including disposition (approval/denial/appeal including peer-to-peer [P2P] review) and perceived impact on patient care and administrative workload. Outcomes included treatment delays, changes from recommended treatment, and patient event including hospitalization, ED visits, permanent disability, or death. Descriptive statistics evaluated responses. Results: Of 736 responding radiation oncologists (16% response rate), 83% reported a rise in PA over the past three years, with 58% noting the burden has increased greatly. In the past year, 50% reported that more than half of their cases required PA, with a median approval rate of 75% and median overturn rate of 82% for denials. For more than half of their cases, nearly half of physicians (43%) noted that P2P was a futile effort to overturn PA denials due to insurance policies. Most (75%) reported that PA resulted in their practice needing to reallocate staff; 91% reported worsening burnout due to PA. P2P reviews were particularly burdensome, averaging 1.65 hours per week. A third (30%) reported that PA requirements had caused serious complications for their patients, including 7% who reported PA had contributed to patient death. Almost all (91%) reported PA-related treatment delays for some of their patients, with 58% indicating average delays of ≥5 days. Most (81%) reported that at times they had to use radiation techniques they considered less optimal due to PA, including 58% who were forced to deviate from national guidelines. The most common reasons for not appealing a PA denial were anticipated delays (73%), perceived futility based on prior PA experiences (62%), and administrative burden (45%). Conclusions: The administrative and clinical burdens associated with PA have significant implications for patient care, physician well-being, and healthcare resource allocation in RO. Treatment delays, compromised therapies, and adverse patient outcomes are commonly reported and underscore the need for PA reform to improve patient outcomes, reduce physician burnout, and improve efficiency.
Heterogeneity in Racial and Ethnic Disparities in COVID-19 Severity Among Pediatric Inpatients in a National Healthcare Database
Watson, David , Spaulding, Alicen B. , Norton, L. J. , Norton, Laura

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | October 7, 2025 | Volume: 14 | Issue: 10 | Pages: No page available

10.1093/jpids/piaf092 | PMID 41060298 Get It

Abstract Background The COVID-19 pandemic magnified longstanding racial and ethnic disparities in pediatric health, but it is unclear which populations experienced the largest disparities. Our objective was to determine whether disparities in COVID-19 severity differed with respect to patient factors analyzed as effect modifiers. Methods Using data from the Premier Healthcare Database, this retrospective cohort study included encounters among inpatients < 19 years old from April 2020 through September 2022 in the USA with a COVID-19 diagnosis. Outcomes of COVID-19 severity were intensive care unit (ICU) admission and ventilator use. Comparisons between Black and White patients and Hispanic and White patients were adjusted for confounders using propensity score weights, reported as risk differences (RDs) in percentage points, and tested for heterogeneity (interaction P) across subgroups of effect modifiers such as complex chronic conditions (CCCs) and insurance status. Results Of 8947 pediatric inpatients with primary COVID-19 diagnosis, 3858 were White, 2153 were Black, and 2936 were Hispanic. Among children with a CCC, 14.3% of Black inpatients required a ventilator compared to 9.8% of White inpatients; among children without a CCC, 3.2% of both Black and White inpatients required a ventilator (RDs 4.5 vs 0.0; interaction P = .013). Comparisons of Hispanic and White inpatients showed a similar trend in ventilator use, with larger disparities among inpatients with CCCs and no difference among those without CCCs (RDs 2.7 vs −0.7; interaction P=.031). Among children with government insurance, 25.9% of Black inpatients were admitted to the ICU compared to 20.8% of White inpatients; among children with private insurance, Black and White inpatients had comparable ICU admission rates of 20.0% and 21.4%, respectively (RDs 5.1 vs −1.4; interaction P = .025). Conclusions Among hospitalized children, racial and ethnic disparities in COVID-19 severity were largest for those with CCCs or government insurance. These results can help identify target populations for interventions to reduce inequity.